ClinicalTrials.gg
RecruitingNCT06334952GALVANI GS-3Updated Dec 19, 2025

Efficacy of Personnalized Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epileptic

An interventional study of transcranial direct current stimulation in Epilepsy and Drug Resistant Epilepsy, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 7 sites in France. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.

Primary conditionDrug Resistant EpilepsyRegistry: EpilepsyReclassifiedWhy we changed it
Registry
Epilepsy — the first condition term the registry derived for this study.
ClinicalTrials.gg
Drug Resistant Epilepsy
Why
  1. The study's listed conditions name Drug Resistant Epilepsy, a narrower term within Epilepsy.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
9 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Drug Resistant Epilepsy with a site in France — 16 open to participants now, 17 under way, 1 of them phase 3. Drug Resistant Epilepsy · France.

Planned enrollment
15th of 24
60 · median 82
Started
2024
with 6 others
No phase
12 of 35
8 open now
Primary completion
2026-12
later than 3 of 16 live
Registered
28th of 35
by date
Lead sponsor
3 of 35
Assistance Publique Hopitaux De Marseille

Among the 35 studies in Drug Resistant Epilepsy with a site in France, this one is the 15th largest by planned enrollment of the 24 interventional ones that give a count, is one of 7 that started in 2024, is one of 12 with no phase, reaches primary completion later than 3 of the 16 other live ones, and was the 28th registered.

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

16 of the 35 studies in Drug Resistant Epilepsy with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.

This study: 9 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Drug Resistant Epilepsy with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical trial is to to obtain a significant decrease in seizure frequency in patients with refractory focal epilepsy after applying treatment of cathodal tDCS, compared to sham stimulation drug-resistant epileptic patient. The main questions it aims to answer are:

  • Changes in quality of life
  • Percent of newly reported side effects after the stimulation period
  • Scores in epilepsy severity. Participants will be randomized in a cross-over, and will receive 10 days of tDCS or Sham. Each day will allow 2 periods of 20 minutes stimulation separated by 20 minutes off (with 40 minutes of cathodal stimulation total).
03

Conditions studied

  • Epilepsy
  • Drug Resistant Epilepsy

Browse trials for

Keywords

  • epilepsy
  • transcranial direct current stimulation
  • numerical models
  • quality of life
04

In context

Drug Resistant Epilepsy Reclassified

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

This study's planned enrollment of 60 is above the median of 30 across 202 interventional studies indexed under Drug Resistant Epilepsy.

Browse Drug Resistant Epilepsy studies →

Lead sponsor

Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.

Compared within Drug Resistant Epilepsy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient, parents or legal representative who have given written ;
  2. Age: ≥ 9 years;
  3. Patients with drug-resistant focal epilepsy with no evolutive brain lesion and no surgical indication or with a previous surgical failure, refusing surgery or with a planned surgery compatible with the total duration of this study;
  4. SEEG previously performed before inclusion with an adequate definition of the epileptogenic zone with all data required (pre-SEEG MRI, CT-scan or MRI with electrodes during SEEG and SEEG files) for personalization ;
  5. Patient having a pre-SEEG 3D-T1 MRI and CT-scan with electrodes during SEEG available; This MRI can be done specifically for this trial or might be reused from EPINOV or NEURO7T trial)
  6. For patients with VNS, experiencing no response or partial response, and for whom the stimulation parameters have been stable for at least 6 months
  7. A research MRI scan that is suitable for navigated brain stimulation (NBS) and generation of electrical fields including dMRI for tractography;
  8. Number of seizures ≥3/month during the baseline (before the first session of tDCS treatment);
  9. Patient having stable medications for epilepsy 4 weeks before the baseline (except rescue treatment);
  10. Patient's IQ, which in the investigator's opinion will enable questionnaires and neuropsychological assessments to be carried out;
  11. Patient able to understand, speak and write in French;
  12. Patient able to follow study's procedure;
  13. Patient beneficiary or affiliated to a health insurance plan.

Exclusion criteria

Exclusion Criteria:

  1. Patients with seizures of generalized onset in the last 12 months;
  2. Patient with multifocal epileptogenic zones, bilateral epileptogenic zone, or poorly defined epileptogenic zone. The epileptogenic network should not be restricted to the orbito frontal cortex or cingulate cortex;
  3. Patients with psychogenic nonepileptic seizures;
  4. Patient presenting a to MRI 3T (patient having a pacemaker, metallic foreign bodies, non-removably implanted electronic medical devices, claustrophobia, inability to remain in supine position, vagus nerve stimulator even when switched off is a contraindication for MRI 3T. EPINOV or NEURO 7T trial patients, who have accepted for their data to be reused, can be included even while wearing a VNS device) ;
  5. Substance use abuse that may include alcohol , opioids (heroin, fentanyl) stimulants (Cocaine, methamphetamine) , hallucinogens (LSD, psilocybin (magic mushrooms), MDMA (Ecstasy))
  6. Patient presenting a serious intercurrent pathology and/or a progressive brain tumor
  7. Patient having damaged skin or scalp that may interfere with tDCS stimulation (e.g., eczema, lesion);
  8. Patient having any cranial metal implants such as shrapnel or surgical clips (excluding \<1 mm thick epicranial titanium skull plates and dental fillings) or medical devices (i.e. cardiac pacemaker, deep brain stimulator, medication infusion pump, cochlear implant)
  9. Patient having previous surgeries opening the skull leaving skull defects capable of allowing the insertion of a cylinder with a radius greater or equal to 5 mm;
  10. Any condition that makes the study subject, in the opinion of the investigator, unsuitable for the study including presence of any disease, abnormality, medical or physical condition that, in the opinion of the investigator, may adversely impact, compromise, interfere, limit, affect or reduce the safety of the subject, the integrity of the data ;
  11. Person protected by articles L1121-5, L1121-6 of Public Health Code (pregnant or breastfeeding woman, deprived of liberty by judicial decision, situations of social fragility, adults unable or unable to express their consent, person under judicial safeguard (article L1122-2)).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Other
    tDCS - Sham

    Patient will be randomized to firstly receive tDCS (10 non consecutive days, 20 minutes twice a day with 20 minutes of break) and then Sham (10 non consecutive days, 20 minutes twice a day with 20 minutes of break).

    Device: transcranial direct current stimulation

  • Other
    Sham - tDCS

    Patient will be randomized to firstly receive Sham (10 non consecutive days, 20 minutes twice a day with 20 minutes of break) and then tDCS (10 non consecutive days, 20 minutes twice a day with 20 minutes of break).

    Device: transcranial direct current stimulation

Interventions

  • Devicetranscranial direct current stimulation

    Research MRI includes 3D-T1 weighted MRI (3D-T1), diffusion MRI (dMRI), resting-state functional MRI (rsfMRI).

    Also known as: Research MRI, EEG

07

What researchers measure

Primary outcomes

  1. To obtain a significant seizure frequency change at the end of tDCS sessions compared to the seizure frequency calculated in the pre-treatment period of reference.

    Seizure frequency counting after end of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study.

    Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)

  2. To obtain a significant seizure frequency change at the end of tDCS sessions compared to the seizure frequency calculated in the pre-treatment period of reference.

    Seizure frequency counting after end of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study.

    Time frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)

  3. To obtain a significant seizure frequency change at the end of tDCS sessions compared to the seizure frequency calculated in the pre-treatment period of reference.

    Seizure frequency counting after end of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study.

    Time frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)

  4. To obtain a significant seizure frequency change at the end of tDCS sessions compared to the seizure frequency calculated in the pre-treatment period of reference.

    Seizure frequency counting after end of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study.

    Time frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)

Secondary outcomes

  1. Evaluation of the number of responders (defined as patient with >50% of seizure reduction)

    Proportion of responders evaluated after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study

    Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)

  2. Evaluation of the number of responders (defined as patient with >50% of seizure reduction)

    Proportion of responders evaluated after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study

    Time frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)

  3. Evaluation of the number of responders (defined as patient with >50% of seizure reduction)

    Proportion of responders evaluated after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study

    Time frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)

  4. Evaluation of the number of responders (defined as patient with >50% of seizure reduction)

    Proportion of responders evaluated after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study

    Time frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)

  5. Evaluate the number of seizure-free patients

    Number of seizure-free patients after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study

    Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)

  6. Evaluate the number of seizure-free patients

    Number of seizure-free patients after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study

    Time frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)

  7. Evaluate the number of seizure-free patients

    Number of seizure-free patients after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study

    Time frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)

  8. Evaluate the number of seizure-free patients

    Number of seizure-free patients after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study

    Time frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)

  9. Quality of life after stimulation sessions with the baseline period

    Changes from baseline in the quality of life questionnaire (QOLIE 31 for adults and EFIQUACEE QOL for children) after the stimulation period

    Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)

  10. Quality of life after stimulation sessions with the baseline period

    Changes from baseline in the quality of life questionnaire (QOLIE 31 for adults and EFIQUACEE QOL for children) after the stimulation period

    Time frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)

  11. Quality of life after stimulation sessions with the baseline period

    Changes from baseline in the quality of life questionnaire (QOLIE 31 for adults and EFIQUACEE QOL for children) after the stimulation period

    Time frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)

  12. Quality of life after stimulation sessions with the baseline period

    Changes from baseline in the quality of life questionnaire (QOLIE 31 for adults and EFIQUACEE QOL for children) after the stimulation period

    Time frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)

  13. Evaluation of the change in seizure severity

    Changes in the scores of epilepsy severity (NHS3) (investigator evaluation)

    Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)

  14. Evaluation of the change in seizure severity

    Changes in the scores of epilepsy severity (NHS3) (investigator evaluation)

    Time frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)

  15. Evaluation of the change in seizure severity

    Changes in the scores of epilepsy severity (NHS3) (investigator evaluation)

    Time frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)

  16. Evaluation of the change in seizure severity

    Changes in the scores of epilepsy severity (NHS3) (investigator evaluation)

    Time frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)

  17. Changes in psychiatric comorbidities

    Changes from baseline in depression (NDDI-E) and anxiety (GAD-7) scores

    Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)

  18. Changes in psychiatric comorbidities

    Changes from baseline in depression (NDDI-E) and anxiety (GAD-7) scores

    Time frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)

  19. Changes in psychiatric comorbidities

    Changes from baseline in depression (NDDI-E) and anxiety (GAD-7) scores

    Time frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)

  20. Changes in psychiatric comorbidities

    Changes from baseline in depression (NDDI-E) and anxiety (GAD-7) scores

    Time frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)

  21. Safety assessment and possible side effects

    Percent of newly reported side-effect during and after the stimulation period

    Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)

  22. Safety assessment and possible side effects

    Percent of newly reported side-effect during and after the stimulation period

    Time frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)

  23. Safety assessment and possible side effects

    Percent of newly reported side-effect during and after the stimulation period

    Time frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)

  24. Safety assessment and possible side effects

    Percent of newly reported side-effect during and after the stimulation period

    Time frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)

Other outcomes

  1. Compare brain functional connectivity before and after tDCS treatment

    Changes in functional connectivity measured by fMRI and EEG signal 4 weeks after the tDCS periods in comparison with baseline period

    Time frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)

  2. Evaluation of the impact of tDCS on interictal epileptic spikes (IESs)

    Change in the number of IESs per time unit after each tDCS session in comparison with baseline period

    Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)

  3. Evaluation of the impact of tDCS on interictal epileptic spikes

    Change in localization and extent of brain areas involved in IESs before and after each tDCS session in comparison with baseline period

    Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)

  4. Evaluation of the impact of tDCS on interictal epileptic spikes

    Change in localization and extent of brain areas involved in IESs before and after each tDCS session in comparison with baseline period

    Time frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)

  5. Evaluation of the impact of tDCS on interictal epileptic spikes

    Changes in strength and density of functional links during IES before and after each tDCS session

    Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)

  6. Evaluation of the impact of tDCS on interictal epileptic spikes

    Changes in strength and density of functional links during IES before and after each DCS session

    Time frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)

08

Study locations

3 of 7 sites recruiting
  • Service de Neurophysiologie Clinique de l'Enfant et de L'Adulte, Pôle de Neurosciences Cliniques
    Bordeaux, 33000, France
    Recruiting
  • Département Neurologie Fonctionnelle et Epilepsie, Hôpital neurologique - Hospices Civils de Lyon
    Bron, 69677, France
    Recruiting
  • Service de Neurophysiologie clinique - Hôpital Roger Salengro, CHU Lille
    Lille, 59037, France
    Not yet recruiting
  • Service Epileptologie et Rythmologie Cérébrale, Hôpital La Timone
    Marseille, 13005, France
    Recruiting
  • Service de Neurophysiologie clinique - GHU Psychiatrie et Neurosciences Sainte-Anne
    Paris, 75014, France
    Not yet recruiting
  • Service de Neurologie - CHU de Rennes - Hôpital Pontchaillou
    Rennes, 35033, France
    Not yet recruiting
  • Explorations neurophysiologiques - Pôle neurosciences, CHU de Toulouse, Hôpital Pierre Paul Riquet
    Toulouse, 31059, France
    Not yet recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

Of 90 non-industry interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21. This study's planned 24 months is below that.

Counting every sponsor, half of 102 studies reached it within 34 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2024
First posted
Mar 28, 2024
StartActual
Dec 18, 2024
Primary completionEst.
Dec 18, 2026
CompletionEst.
Jan 18, 2028
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06334952
Collaborators
CRMBM-CEMEREM, Institut National de la Santé Et de la Recherche Médicale, France, Neuroelectrics Corporation
Responsible party
Sponsor
First posted
Mar 28, 2024
Start date
Dec 18, 2024
Primary completion
Dec 18, 2026 (estimated)
Completion
Jan 18, 2028 (estimated)
Last update
Dec 19, 2025

Study contacts

Fabrice Bartolomei, MD, PhD
Contact
fabrice.bartolomei@ap-hpm.fr
0491384990 ext. 33
Sophie Tardoski
Contact
sophie.tardoski@ap-hm.fr
0491381594 ext. 33

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion